Mallinckrodt Recognizes First Hepatorenal Syndrome (HRS) Awareness Day
Mallinckrodt (NYSE:MNK) announced support for the inaugural Hepatorenal Syndrome (HRS) Awareness Day, established by the American Liver Foundation and observed annually on October 14 during National Liver Awareness Month.
The initiative aims to raise awareness, promote early detection and treatment, and share patient experiences. HRS is described in two types: HRS‑AKI (rapid, often requiring hospitalization) and HRS‑CKD (slower progression). The release states HRS affects more than 60,000 Americans annually (~0.01% of the U.S. population) and that hospitalization rates for HRS are increasing. Company and ALF leaders commented on the need to improve visibility and treatment options for patients.
Mallinckrodt (NYSE:MNK) ha annunciato il sostegno al primo Giorno di Consapevolezza della Sindrome Epatorenale (HRS), istituito dall'American Liver Foundation e osservato annualmente il 14 ottobre durante il Mese Nazionale della Consapevolezza sul Fegato.
L'iniziativa mira a aumentare la consapevolezza, promuovere la rilevazione e il trattamento precoce, e condividere le esperienze dei pazienti. La HRS è descritta in due tipi: HRS‑AKI (rapida, spesso richiede ospedalizzazione) e HRS‑CKD (progresso più lento). Il comunicato afferma che l'HRS interessa più di 60.000 americani all'anno (~0,01% della popolazione statunitense) e che i tassi di ospedalizzazione per HRS sono in aumento. I vertici della società e dell'ALF hanno commentato la necessità di migliorare la visibilità e le opzioni di trattamento per i pazienti.
Mallinckrodt (NYSE:MNK) anunció su apoyo al día inaugural de Concienciación sobre el Síndrome Hepatorrenal (HRS), establecido por la American Liver Foundation y que se celebra cada año el 14 de octubre durante el Mes Nacional de Concienciación sobre el Hígado.
La iniciativa tiene como objetivo crear conciencia, promover la detección y el tratamiento tempranos, y compartir las experiencias de los pacientes. El HRS se describe en dos tipos: HRS-AKI (rápida, a menudo requiere hospitalización) y HRS-CKD (progresión más lenta). El comunicado indica que el HRS afecta a más de 60.000 estadounidenses al año (~0,01% de la población de EE. UU.) y que las tasas de hospitalización por HRS están aumentando. Los líderes de la empresa y de ALF comentaron la necesidad de mejorar la visibilidad y las opciones de tratamiento para los pacientes.
Mallinckrodt (NYSE:MNK)는 미국 간 재단(American Liver Foundation)이 제정하고 매년 10월 14일 간 건강 인식의 달 동안 기념되는 첫 번째 간신증후군(Hepatorenal Syndrome, HRS) 인식의 날에 대한 지지를 발표했습니다.
이 이니셔티브의 목표는 인식을 높이고 조기 발견과 치료를 촉진하며 환자 경험을 공유하는 것입니다. HRS는 두 가지 유형으로 설명됩니다: HRS‑AKI (급속하며 종종 입원이 필요함) 및 HRS‑CKD (진행 속도가 느림). 보도 자료에 따르면 HRS는 매년 60,000명 이상의 미국인에게 영향을 미치며(미국 인구의 약 0.01%), HRS로 인한 입원율이 증가하고 있습니다. 회사 및 ALF 관계자들은 환자에 대한 가시성과 치료 옵션을 개선할 필요성에 대해 언급했습니다.
Mallinckrodt (NYSE:MNK) a annoncé son soutien à la première Journée de Sensibilisation au Syndrome Hépatorénal (HRS), instaurée par la American Liver Foundation et observée annuellement le 14 octobre pendant le Mois national de la sensibilisation au foie.
L'initiative vise à sensibiliser, favoriser la détection et le traitement précoces, et partager les expériences des patients. Le HRS est décrit en deux types : HRS‑AKI (rapide, nécessitant souvent une hospitalisation) et HRS‑CKD (progrès plus lent). Le communiqué indique que le HRS affecte plus de 60 000 Américains chaque année (~0,01% de la population américaine) et que les taux d'hospitalisation pour le HRS sont en augmentation. Des dirigeants de la société et de l'ALF ont souligné la nécessité d'améliorer la visibilité et les options de traitement pour les patients.
Mallinckrodt (NYSE:MNK) kündigte Unterstützung für den inaugurierten Hepatorenal Syndrome (HRS) Awareness Day an, der von der American Liver Foundation eingerichtet wurde und jährlich am 14. Oktober im Rahmen des National Liver Awareness Month begangen wird.
Die Initiative zielt darauf ab, das Bewusstsein zu erhöhen, eine frühzeitige Erkennung und Behandlung zu fördern und die Erfahrungen der Patienten zu teilen. HRS wird in zwei Typen beschrieben: HRS‑AKI (schnell, oft hospitalisierungsbedürftig) und HRS‑CKD (langsamer Fortschritt). Die Mitteilung besagt, dass HRS mehr als 60.000 Amerikaner pro Jahr betrifft (~0,01% der US-Bevölkerung) und die Hospitalisierungsraten für HRS zunehmen. Unternehmens- und ALF-Führungskräfte kommentierten die Notwendigkeit, Sichtbarkeit und Behandlungsoptionen für Patienten zu verbessern.
Mallinckrodt (NYSE:MNK) أعلنت عن دعمها لأول يوم التوعية بمتلازمة الكبد والكُلى الهيمونية (HRS)، الذي أنشأته American Liver Foundation ويُلاحظ سنوياً في 14 أكتوبر خلال شهر التوعية الوطنية بالكبد.
تهدف المبادرة إلى رفع الوعي، تعزيز الكشف المبكر والعلاج، ومشاركة تجارب المرضى. تُوصف HRS بنوعين: HRS‑AKI (سريع، غالباً ما يحتاج إلى دخول المستشفى) و
Mallinckrodt (NYSE:MNK) 宣布支持首届肝肾综合征(HRS) 宣传日，该日由美国肝病基金会设立，并在每年的肝脏健康月10月14日进行纪念。
该倡议旨在提高意识、促进早期发现与治疗，并分享患者经历。HRS 分为两种类型：HRS‑AKI（快速，通常需要住院）和 HRS‑CKD（进展较慢）。新闻稿称 HRS 每年影响超过 6万名美国人（约占美国人口的 0.01%），且因 HRS 的住院率正在上升。公司与 ALF 的领导者就需要提高对患者的可见度和治疗选项发表了评论。
- None.
- None.
– HRS Awareness Day will be observed annually on October 14 during National Liver Awareness Month, with the goal of raising awareness around a life-threatening condition that occurs in people with advanced liver disease1–
HRS is classified into two distinct types – a rapidly progressive type that leads to renal failure where patients are typically hospitalized for their care (HRS-acute kidney injury (AKI)) and a more chronic type that progresses slowly over weeks to months (HRS-chronic kidney disease (CKD)).1,2 HRS is estimated to affect more than 60,000 Americans annually, approximately
"We're proud to support this moment for the HRS community and help to raise visibility of this condition and the patients, care teams, and healthcare professionals it impacts," said Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer, Mallinckrodt. "
"HRS is a life-threatening complication of liver disease,1 so it is fitting to elevate knowledge about this condition and recognize those affected by it during National Liver Awareness Month," said Lorraine Stiehl, CEO, American Liver Foundation. "Thank you to our sponsors, including Mallinckrodt, who have made this awareness day possible and are committed to bringing treatment options to patients in need."
ABOUT MALLINCKRODT
Mallinckrodt is dedicated to enhancing lives by providing therapeutics that strive to address unmet patient needs, and is a world-class manufacturer of high-quality generics, sterile injectables, and active pharmaceutical ingredients.
Our company consists of multiple wholly owned subsidiaries that operate in two businesses. Our Brands business is focused on autoimmune and rare diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients. To learn more, visit www.MNK-Endo.com.
CONTACT
Media Inquiries
Green Room Communications
908-577-4531
mediainquiries@grcomms.com
Investor Relations
Juan Avendano
862-240-8194
avendano.juan@endo.com
Patient Advocacy
Derek Naten
202-257-5904
derek.naten@mnk.com
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.
©2025 Mallinckrodt. US-2500552 10/25
References
1 National Organization for Rare Disorders. Hepatorenal Syndrome. Available at: https://rarediseases.org/rare-diseases/hepatorenal-syndrome/. Accessed October 2025.
2 Flamm S.L., Brown K., Wadei H.M., et al. The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in
3 United States Census Bureau: Quick Facts. Available at: https://www.census.gov/quickfacts/fact/table/US/PST045218. Accessed October 2025.
4 Wong R.J., Balasubramanain J., Panaccio M., et al. Acute Kidney Injury and Hepatorenal Syndrome Among Hospitalized Patients With Chronic Liver Disease. JAMA Netw Open. 2025;8(5):e2511816. doi:10.1001/jamanetworkopen.2025.11816
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-recognizes-first-hepatorenal-syndrome-hrs-awareness-day-302582664.html
SOURCE Mallinckrodt plc
FAQ
What did Mallinckrodt (MNK) announce on October 14, 2025?
When is Hepatorenal Syndrome (HRS) Awareness Day observed for MNK and others?
How many Americans does Mallinckrodt say are affected by HRS each year?
What are the two types of HRS described in Mallinckrodt's announcement?
What is the purpose of HRS Awareness Day according to Mallinckrodt (MNK)?
